CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 359 enrolled
Drug / intervention
Warfarindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00964353
NCT00964353Phase 4Completed
CompareCT.gov

The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management

University of Chicago·interventional·Posted Aug 24, 2009·Updated Nov 25, 2019

In Brief

A Phase 4 clinical trial evaluating Warfarin for Blood Coagulation Disorders. Completed, enrolled 359 participants across 1 site.

Detailed Summary

The purpose of this study is to explore how knowing genes that individuals inherit from their parents can make warfarin dosing more safe and effective. This study is being done to determine whether providing doctors with data on the genes their patients inherited and warfarin dosing recommendations based on those genes affects the costs and outcomes of care and after hospitalization for patients from different ethnic/racial backgrounds, and how physicians use this information in decision making.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Coagulation Disorders
CountriesUnited States
CollaboratorsAgency for Healthcare Research and Quality (AHRQ)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2009
Enrollment StartAug 1, 2009
Primary CompletionAug 1, 2012
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.9 years ago

Interventions

Warfarindrug

Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.